Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Synergistic Activity of BMS-986397, a First-in-Class a Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Targeting Casein Kinase 1α (CK1α), in Combination with Venetoclax and/or Azacitidine in Preclinical Models of Acute Myeloid Leukemia (AML)

Carmen Jimenez, Jose Francisco Lopez, Estela Garcia, Laura Diaz Regalado, Alejandro Panjkovich, Sophie Peng, Rama Krishna Narla, Noelia Purroy, Mark Rolfe, Daniel W. Pierce, Soraya Carrancio

Blood (2024) 144 (Supplement 1): 1395.

https://doi.org/10.1182/blood-2024-210023

Published: 2024

Journal Articles

BMS-986397, a First-in-Class Molecular Glue Degrader of Casein Kinase 1α (CK1α) for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Harboring Functional TP53

Carmen Jimenez, Sophie Peng, Rama Krishna Narla, Joshua Baughman, Scott Wood, Jean Lu, Noelia Purroy, Gina Yanochko, Mark Nagy, Gang Lu, Mark Rolfe, Daniel W. Pierce, Soraya Carrancio

Blood (2024) 144 (Supplement 1): 4142.

https://doi.org/10.1182/blood-2024-209924

Published: 2024

Journal Articles

Compassionate Use of Belantamab Mafodotin for Treatment of Patients with Relapsed/Refractory Multiple Myeloma Heavily Treated. Spanish Experience

Blood (2021) 138 (Supplement 1): 3775.

https://doi.org/10.1182/blood-2021-151267

Published: 2021

Journal Articles

R-COMP Vs. R-CHOP As First-Line Treatment for De Novo Diffuse Large B-Cell Lymphoma in Patients Older Than 60 Years: Preliminary Results from a Prospective Randomized Phase 2 Study from the Spanish Group Geltamo

Juan-Manuel Sancho, Francisco Gual, Rubén Fernández-Alvarez, Esther González-García, MD, Carlos Grande, MD PhD, Carmen Jiménez-López, Norma C Gutierrez, MD PhD, María-José Peñarrubia, Ana Batlle, Eva González-Barca, MD PhD, Jose-Maria Guinea-de-Castro, Eva Gimeno, MD PhD, Francisco-Javier Peñalver, MD, Miguel A Fuertes, Jorge Gayoso, MD, José-Ángel Hernández-Rivas, José-María Moraleda, MD PhD, Lluis Virgili, Alejandro Martín, MD PhD

Blood (2016) 128 (22): 5387.

https://doi.org/10.1182/blood.V128.22.5387.5387

Published: 2016

Journal Articles

Long-Term Outcome and Prognostic Factors after Single-Unit Umbilical Cord-Blood Transplantation (UCBT) for Adults with Hematologic Malignancies.

Guillermo Sanz, MD, Susana Cantero, MD, Luis Larrea, MD, Dolores Planelles, PhD, Ignacio Lorenzo, MD, Barbara Banlloch, PhD, Luis Banlloch, PhD, Leonor Senent, MD, Pau Montesinos, MD, Jose Cervera, MD, Carmen Jimenez, MD, Guillermo Martin, MD, Jesus Martinez, MD, Isidro Jarque, MD, Javier De la Rubia, MD, Miguel A. Sanz, MD

Blood (2006) 108 (11): 3129.

https://doi.org/10.1182/blood.V108.11.3129.3129

Published: 2006

Journal Articles

Prophylaxis of Cytomegalovirus (CMV) Infection and Disease after Unrelated-Donor Umbilical Cord-Blood Transplantation (UCBT) with Intravenous Ganciclovir or Oral Valganciclovir.

Guillermo Sanz, MD, PhD, Susana Cantero, MD, Ignacio Lorenzo, MD, PhD, Barbara Benlloch, PhD, Luis Benlloch, PhD, Maria Narvaez, MD, Dolores Planelles, PhD, Luis Larrea, MD, PhD, Isidro Jarque, MD, Phd, Carmen Jimenez, MD, Maria L. Marty, MD, Miguel Gobernado, MD, Miguel A. Sanz, MD, PhD

Blood (2005) 106 (11): 5460.

https://doi.org/10.1182/blood.V106.11.5460.5460

Published: 2005

Journal Articles

Outcome and Prognostic Factors after Unrelated Donor Umbilical Cord Blood Transplantation in Adult Patients with Hematologic Malignancies Transplanted in Early Disease Stages.

Guillermo Sanz, MD, PhD, Ignacio Lorenzo, MD, PhD, Federico Moscardo, MD, Dolores Planelles, PhD, Luis Larrea, MD, PhD, Leonor Senent, MD, Luis Benlloch, PhD, Jaime Sanz, MD, Pau Montesinos, MD, Noemi Puig, MD, Carmen Jimenez, MD, Jesus Martinez, MD, Guillermo Martin, MD, PhD, Isidro Jarque, MD, PhD, Javier de la Rubia, MD, PhD, Maria A. Soler, MD, Maria L. Marty, MD, Miguel A. Sanz, MD, PhD

Blood (2004) 104 (11): 2149.

https://doi.org/10.1182/blood.V104.11.2149.2149

Published: 2004

NARROW

Synergistic Activity of BMS-986397, a First-in-Class a Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Targeting Casein Kinase 1α (CK1α), in Combination with Venetoclax and/or Azacitidine in Preclinical Models of Acute Myeloid Leukemia (AML)

BMS-986397, a First-in-Class Molecular Glue Degrader of Casein Kinase 1α (CK1α) for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Harboring Functional TP53

Compassionate Use of Belantamab Mafodotin for Treatment of Patients with Relapsed/Refractory Multiple Myeloma Heavily Treated. Spanish Experience

R-COMP Vs. R-CHOP As First-Line Treatment for De Novo Diffuse Large B-Cell Lymphoma in Patients Older Than 60 Years: Preliminary Results from a Prospective Randomized Phase 2 Study from the Spanish Group Geltamo

Long-Term Outcome and Prognostic Factors after Single-Unit Umbilical Cord-Blood Transplantation (UCBT) for Adults with Hematologic Malignancies.

Prophylaxis of Cytomegalovirus (CMV) Infection and Disease after Unrelated-Donor Umbilical Cord-Blood Transplantation (UCBT) with Intravenous Ganciclovir or Oral Valganciclovir.

Outcome and Prognostic Factors after Unrelated Donor Umbilical Cord Blood Transplantation in Adult Patients with Hematologic Malignancies Transplanted in Early Disease Stages.

Email alerts

ASH Publications

American Society of Hematology

Synergistic Activity of BMS-986397, a First-in-Class a Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Targeting Casein Kinase 1α (CK1α), in Combination with Venetoclax and/or Azacitidine in Preclinical Models of Acute Myeloid Leukemia (AML)

BMS-986397, a First-in-Class Molecular Glue Degrader of Casein Kinase 1α (CK1α) for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Harboring Functional TP53

Compassionate Use of Belantamab Mafodotin for Treatment of Patients with Relapsed/Refractory Multiple Myeloma Heavily Treated. Spanish Experience

R-COMP Vs. R-CHOP As First-Line Treatment for De Novo Diffuse Large B-Cell Lymphoma in Patients Older Than 60 Years: Preliminary Results from a Prospective Randomized Phase 2 Study from the Spanish Group Geltamo

Long-Term Outcome and Prognostic Factors after Single-Unit Umbilical Cord-Blood Transplantation (UCBT) for Adults with Hematologic Malignancies.

Prophylaxis of Cytomegalovirus (CMV) Infection and Disease after Unrelated-Donor Umbilical Cord-Blood Transplantation (UCBT) with Intravenous Ganciclovir or Oral Valganciclovir.

Outcome and Prognostic Factors after Unrelated Donor Umbilical Cord Blood Transplantation in Adult Patients with Hematologic Malignancies Transplanted in Early Disease Stages.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only